Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Guggenheim Analyst Says

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective hoisted by equities researchers at Guggenheim from $140.00 to $143.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 54.21% from the company’s previous close.

Several other brokerages have also issued reports on RYTM. Canaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the company a “buy” rating in a research report on Friday, December 12th. HC Wainwright raised their price objective on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Royal Bank Of Canada assumed coverage on shares of Rhythm Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $145.00 price objective for the company. Oppenheimer cut Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Finally, Needham & Company LLC raised their price target on Rhythm Pharmaceuticals from $145.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.71.

Rhythm Pharmaceuticals Stock Down 5.4%

Rhythm Pharmaceuticals stock opened at $92.73 on Friday. The stock has a market cap of $6.19 billion, a price-to-earnings ratio of -29.82 and a beta of 2.00. The business has a 50-day simple moving average of $103.90 and a 200 day simple moving average of $103.54. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 378.31% and a negative net margin of 103.57%.The firm had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. During the same quarter last year, the company posted ($0.72) EPS. The company’s revenue for the quarter was up 36.9% on a year-over-year basis. On average, research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Activity

In related news, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares in the company, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the transaction, the insider owned 20,814 shares in the company, valued at approximately $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 25,003 shares of company stock valued at $2,589,015. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors have recently modified their holdings of RYTM. RA Capital Management L.P. increased its holdings in Rhythm Pharmaceuticals by 17.3% during the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock valued at $713,618,000 after purchasing an additional 985,478 shares during the period. Vanguard Group Inc. grew its position in shares of Rhythm Pharmaceuticals by 24.3% in the 4th quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company’s stock worth $664,816,000 after buying an additional 1,214,489 shares during the last quarter. State Street Corp increased its stake in shares of Rhythm Pharmaceuticals by 8.4% during the fourth quarter. State Street Corp now owns 2,198,615 shares of the company’s stock valued at $235,340,000 after buying an additional 169,964 shares during the period. Federated Hermes Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 2.5% during the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after acquiring an additional 41,391 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Rhythm Pharmaceuticals by 21.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock valued at $102,966,000 after acquiring an additional 288,376 shares in the last quarter.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat estimates: EPS of $-0.73 vs. consensus of $-0.79 and revenue of $57.25M (y/y revenue +36.9%). The beat supports commercial traction for IMCIVREE. Zacks: Rhythm Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst upgrade/target raise: Citizens JMP raised its price target to $176 and kept a “market outperform” rating, signaling strong upside to Street models. Benzinga: Citizens JMP raises PT
• Positive Sentiment: Analyst raise: Guggenheim lifted its target to $143 and maintained a “buy” rating, adding another constructive analyst signal. Benzinga: Guggenheim raises PT
• Positive Sentiment: Near‑term clinical/regulatory catalysts remain: PDUFA goal date for the sNDA in acquired hypothalamic obesity on March 20, plus March topline readouts from Phase 3 programs (EMANATE and a Japanese cohort) that could significantly re‑rate the story. GlobeNewswire: Rhythm Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst trim but still constructive: Wells Fargo cut its target to $136 but kept an “overweight” rating, signaling continued confidence despite a smaller upside. Benzinga: Wells Fargo lowers PT
• Neutral Sentiment: Needham lowered its target to $139 but maintained a “buy”—another sign that sell‑side views remain broadly positive even as models are adjusted. TickerReport: Needham lowers PT
• Negative Sentiment: Large near‑term spending guide: Rhythm told investors it expects $385M–$415M in 2026 non‑GAAP operating expenses as hypothalamic‑obesity (HO) launch preparations accelerate — higher burn that may pressure margins and cash runway in the near term. Seeking Alpha: Rhythm anticipates $385M–$415M in 2026 non‑GAAP operating expenses

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.